Due to the rarity of the<unk> , data regarding treatment is limited to observational case series and case reports. No randomized trials have been conducted comparing treatment options for UCD. Complete surgical removal of the enlarged lymph node or region of lymph nodes is considered the gold standard treatment for UCD and is typically curative, with resolution of symptoms and lab abnormalities attributable to the<unk> . Occasionally, surgical removal of an enlarged lymph node may be prohibitively high risk at the time of diagnosis due to large size or proximity to critical structures. This is more common with lymph nodes located deep in the chest, which may be close to major airways and blood vessels. In these cases, chemotherapy, immunosuppressive medications, catheter embolization of blood vessels supplying the lymph node, and/or radiation therapy may be used to shrink the involved lymph nodes, potentially reducing the risk of surgery to acceptable levels. If surgical risk remains too high after treatment to shrink the enlarged lymph node, treatments used to reduce the size of the lymph node may be continued to control symptoms related to the<unk> . Follow-up After initiation of treatment, patients are regularly evaluated for recurrence of<unk>  and response to treatment with laboratory testing and radiologic imaging.
Unicentric Castleman disease
Idiopathic multicentric Castleman disease
Follicular lymphoma
Follicular dendritic cell sarcoma
Progressive nodular histiocytoma
Thymic carcinoma
Marginal zone B-cell lymphoma
Progressive nodular histiocytosis